质子泵抑制剂治疗胃食管反流病比钾竞争性酸阻断剂更具成本效益
该研究构建决策树模型,比较钾竞争性酸阻断剂(PCAB)与质子泵抑制剂(PPI)作为胃食管反流病(GERD)一线治疗的成本效益。结果显示PCAB费用比PPI高3240美元,增量成本效益比为144208美元/QALY,超过100000美元/QALY的支付意愿阈值,概率敏感性分析中PPI在71.7%的迭代中更优。
要点
- PCAB治疗GERD的费用比PPI高3240美元,增量成本效益比144208美元/QALY。
- 在非糜烂性反流病、LA A/B和LA C/D食管炎各表型中,PCAB的增量成本效益比均超过支付意愿阈值。
- 概率敏感性分析100000次迭代中PPI有71.7%概率更具成本效益。
核心结论
- 尽管PCAB疗效更优,PPI仍是GERD治疗中具成本效益的策略,可置于PCAB升级之前。
- 降低PCAB费用或接受更高支付意愿阈值可能改变结论,但概率敏感性分析显示PPI更优。
研究设计与样本
- 构建决策树模型,基础病例为GERD患者,比较PCAB与PPI作为一线治疗,包括症状持续时的升级治疗和/或换药。
- 采用公开费用数据,从社会视角在6个月时比较质量调整生命年(QALY),支付意愿阈值为100000美元/QALY。
主要发现
- PCAB治疗GERD的费用比PPI高3240美元,增量成本效益比为144208美元/QALY。
- 按GERD表型(非糜烂性反流病、LA A/B、LA C/D食管炎)分别分析,增量成本效益比均超过支付意愿阈值。
- 单因素分析显示最具影响的参数为PCAB费用和无烧心天数疗效。
- 概率敏感性分析100000次迭代中PPI有71.7%概率更优。
- 将一周费用降至91美元以下可使PCAB成为所有GERD表型中具成本效益的一线策略。
临床怎么用
- 基于成本效益,PPI可作为GERD的一线治疗,优先于PCAB升级。
- 若PCAB费用显著降低或支付意愿阈值提高,可考虑PCAB作为一线选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Potassium competitive acid blockers (PCABs) are superior to proton pump inhibitors (PPIs) for healing of Los Angeles (LA) class C/D erosive esophagitis and are approved for nonerosive gastroesophageal reflux disease (GERD) given their efficacy measured by heartburn-free days. However, they are more expensive than PPIs. We estimated the cost-effectiveness of PCABs compared with PPIs for the management of GERD. METHODS: A decision tree was constructed for the base case of a patient with GERD. We tested scenarios in which nonerosive reflux disease, LA A/B, or LA C/D esophagitis was present, comparing PCABs with PPIs as first-line therapy, including step up therapy and/or class switching if symptoms persisted. Using publicly available cost estimates, quality-adjusted life years (QALYs) were compared using a willingness-to-pay threshold of $100,000/QALY from a societal perspective at 6 months. RESULTS: The cost of PCABs for GERD was $3,240 more than PPIs, with an incremental cost-effectiveness ratio of $144,208/QALY. When evaluating GERD phenotypes separately, the incremental cost-effectiveness ratio was consistently over our willingness-to-pay threshold. One-way analyses showed the most influential parameters were PCAB cost and efficacy for heartburn-free days. Probabilistic sensitivity analysis favored PPIs 71.7% out of 100,000 iterations. Reducing one-week costs to below $91 would make PCABs a cost effective first-line strategy across all GERD phenotypes. DISCUSSION: Despite PCAB efficacy, PPIs are a cost-effective strategy for GERD treatment, and can be positioned ahead of PCAB escalation on this basis. Reducing PCAB costs or accepting a higher willingness-to-pay threshold would influence this finding, although PCABs may be favored in some current situations as evidenced by probabilistic sensitivity results.
引用
- Karlin KL, Gilbert EH, Lim F, et al. Proton Pump Inhibitors Are More Cost-Effective Than Potassium Competitive Acid Blockers for Gastroesophageal Reflux Disease. Am J Gastroenterol. 2026. PMID: 41665233. doi:10.14309/ajg.0000000000003943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。